NanoViricides, Inc. NNVC
1.33 USD +0.01 (+0.76%)
At closeNov 10, 2026, 4:47 AM EST
1.27 -0.06 -4.49%
Pre-market · Nov 10, 4:47 AM ET
1.30 Day range 1.39
0.85 52-week range 2.03
- YTD
- +17.70%
- 1 year
- -20.83%
News
benzinga.com NanoViricides Announces That NV-387 Successfully Demonstrated Strong Safety, Tolerability, And Toxicological Parameters In An Animal Model Study Involving Juvenile Mouse Pups This study is expected to pave the way for pediatric use of NV-387 in clinical trials in children possibly as young as 1 year old. Pediatric drugs for Ebola, Mpox, and Measles, as well as RSV - to…
benzinga.com NanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well The Phase IIA part of the clinical trial is designed to evaluate different dosage regimens of the oral gummies for the treatment of different severity levels of the Ebola Bundibugyo virus infection…